Abstract
AbstractBRL 26850A has been extensively reported 1 as a novel β‐adrenoceptor agonist. In order to perform metabolism studies, carbon‐14 radiolabelled BRL 26830A was synthesised from potassium [14C]cyanide. As BRL 26830A contains two asymmetric centres, the initial product required resolution of the two enantiomeric pairs. This was achieved by sequential fractional crystallisation of the free base and then the hydrobromide salt to obtain the required (R*, R*)‐(+) enantiomeric pair before final conversion to the hemifumarate salt ([14C]BRL 26830A).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Labelled Compounds and Radiopharmaceuticals
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
